Crinetics pharmaceuticals, inc. (CRNX)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18
Operating activities:
Net loss

-58,766

-50,422

-44,368

-37,526

-30,667

-27,115

0

0

0

Reconciliation of net loss to net cash used in operating activities:
Stock-based compensation

7,413

6,294

5,310

4,231

2,922

2,320

0

0

0

Depreciation and amortization

922

887

866

777

623

471

0

0

0

Noncash lease expense

238

226

0

0

0

-

-

-

-

Accretion of purchase discounts and amortization, net of premiums on investment securities

1,009

1,229

0

0

0

-

-

-

-

Other

26

4

0

0

0

-

0

0

0

Increase (decrease) in cash resulting from changes in:
Prepaid expenses and other current assets

2,463

2,221

1,555

503

607

1,802

0

0

0

Accounts payable and accrued expenses

2,504

696

2,903

3,617

6,073

7,361

0

0

0

Operating lease liability

-665

-608

0

0

0

-

-

-

-

Net cash used in operating activities

-51,852

-46,381

-38,943

-31,029

-22,811

-19,459

0

0

0

Investing activities:
Purchases of investment securities

99,459

108,136

0

0

0

-

-

-

-

Maturities of investment securities

133,010

150,295

0

0

0

-

-

-

-

Purchases of property and equipment

144

492

746

997

1,410

1,059

0

0

0

Net cash provided by investing activities

33,407

41,667

-64,191

-84,890

-94,802

-119,458

0

0

0

Financing activities:
Proceeds from issuance of convertible preferred stock, net

-

-

-

-

-

63,275

0

0

0

Proceeds from issuance of common stock, net

0

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options

161

126

109

145

218

451

0

0

0

Payment of initial public offering costs

-

-

-

-

-

-

-

0

0

Net cash provided by financing activities

6,529

67

59

107,227

106,706

170,198

0

0

0

Net change in cash, cash equivalents and restricted cash

-11,916

-4,647

-103,075

-8,692

-10,907

31,281

0

0

0

Noncash investing and financing activities:
Change in unvested stock liability

51

94

-48

-43

77

21

0

0

0

Amounts accrued for purchases of property and equipment

-

-

-

-

2

42

0

0

0

Change in accrued preferred stock issuance and initial public offering costs

-

-

-

-

-

-

-

-

0